Ibutilide is a class III antiarrhythmic agent used to correct atrial fibrillation and atrial flutter, which can be considered as an alternative to cardioversion. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
- Mechanism
- Curator reviewed
Ibutilide is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca2+ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K+ current, by binding within potassium channel pores. In other words, Ibutilide binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels
- Primary indication
- Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.Curator reviewed · 2 structured indications
- Formula / weight
- C20H36N2O3S · 384.576 g/mol (avg)
- First approval
- Canada, 2016 · United States, 1995
- Code names
- U 70226 E
- Brand names
Resolves to
ALOBUEHUHMBRLE-UHFFFAOYSA-NSMILESCCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Ibutilide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account